Industry News

Cardinal Health to acquire Medtronic Patient Product Portfolio

Centerwatch - Thu, 2017-04-20 10:46

Cardinal Health has entered into a definitive agreement to acquire Medtronic‘s Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses for $6.1 billion in cash. The purchase price does not include cash tax benefits of at least $100 million. The acquisition is expected to be financed with a combination of $4.5 billion in new senior unsecured notes and existing cash. […]

The post Cardinal Health to acquire Medtronic Patient Product Portfolio appeared first on CenterWatch News Online.

Categories: Industry News

Cellular Dynamics International, Harvard Stem Cell Institute to collaborate

Centerwatch - Thu, 2017-04-20 10:42

Cellular Dynamics International (CDI), a FUJIFILM company and a developer and manufacturer of induced pluripotent stem cells (iPS), has signed a collaboration agreement with the Harvard Stem Cell Institute (HSCI), a novel network of stem cell scientists that extends from the University to its affiliated hospitals and the biomedical industry. The objective of the new partnership is […]

The post Cellular Dynamics International, Harvard Stem Cell Institute to collaborate appeared first on CenterWatch News Online.

Categories: Industry News

Verily, Duke and Stanford launch Project Baseline study

Centerwatch - Thu, 2017-04-20 10:33

Verily Life Sciences, an Alphabet company, in partnership with Duke University School of Medicine and Stanford Medicine, announced the initiation of the Project Baseline study, a longitudinal study that will collect broad phenotypic health data from approximately 10,000 participants, who will each be followed over the course of at least four years. The study is […]

The post Verily, Duke and Stanford launch Project Baseline study appeared first on CenterWatch News Online.

Categories: Industry News

Parvus Therapeutics, Novartis partner to treat type 1 diabetes

Centerwatch - Thu, 2017-04-20 10:17

Parvus Therapeutics, a biopharmaceutical company developing disease-modifying nanomedicines to halt or reverse autoimmune disease without causing general immune suppression, has entered into a license and collaboration agreement with Novartis for its lead Navacim for treating type 1 diabetes. Navacims constitute a novel pharmacological class of therapeutic comprised of nanoparticles (NPs) coated with disease-relevant peptide-major histocompatibility […]

The post Parvus Therapeutics, Novartis partner to treat type 1 diabetes appeared first on CenterWatch News Online.

Categories: Industry News

BioMed Realty invests in expanded research facilities at the Babraham Research Campus

Centerwatch - Thu, 2017-04-20 09:29

The Biotechnology and Biological Sciences Research Council (BBSRC), Babraham Bioscience Technologies (BBT) and BioMed Realty, a Blackstone portfolio company, have announced a partnership that will see BioMed Realty signing a long-term lease on approximately eight acres of BBSRC-owned land at the Babraham Research Campus, Cambridge, U.K. The investment will enable the ground-up construction of two new buildings for […]

The post BioMed Realty invests in expanded research facilities at the Babraham Research Campus appeared first on CenterWatch News Online.

Categories: Industry News

Abeome, CDC to collaborate on Zika antibody discovery

Centerwatch - Thu, 2017-04-20 09:23

Abeome has signed a Research Collaboration Agreement (RCA) with Centers for Disease Control and Prevention (CDC) for the identification of novel antibodies binding to the Zika virus using Abeome’s proprietary AbeoMouse platform. “We are very pleased to collaborate with the CDC using our proprietary antibody discovery platform, AbeoMouse, for the rapid discovery of monoclonal antibodies. […]

The post Abeome, CDC to collaborate on Zika antibody discovery appeared first on CenterWatch News Online.

Categories: Industry News

CytoDyn’s PRO 140 for HIV rejected by FDA for Orphan Drug Designation

Centerwatch - Thu, 2017-04-20 09:07

CytoDyn, a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that its application for Orphan Drug Designation (ODD) was not granted by the Office of Orphan Products Development of the FDA because PRO 140 appears to have the potential to treat more than just the […]

The post CytoDyn’s PRO 140 for HIV rejected by FDA for Orphan Drug Designation appeared first on CenterWatch News Online.

Categories: Industry News

Novartis’s CTL019 receives FDA Breakthrough Therapy designation

Centerwatch - Thu, 2017-04-20 08:35

Novartis announced that the FDA has granted Breakthrough Therapy designation to CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with relapsed and refractory (r/r) diffuse large B-cell lymphoma (DLBCL), who have failed two or more prior therapies. This is the second indication for which CTL019 has received […]

The post Novartis’s CTL019 receives FDA Breakthrough Therapy designation appeared first on CenterWatch News Online.

Categories: Industry News

Veeva launches Vault SiteExchange for simple clinical trial document exchange

Centerwatch - Thu, 2017-04-20 08:27

Veeva Systems announced Veeva Vault SiteExchange, a cloud application that allows life sciences companies, CROs and sites to easily access and exchange information during clinical trial execution. Veeva Vault SiteExchange streamlines collaboration among clinical teams for improved visibility across studies and increased operational efficiency to speed the research and development of new treatments. Clinical investigators […]

The post Veeva launches Vault SiteExchange for simple clinical trial document exchange appeared first on CenterWatch News Online.

Categories: Industry News

Bavarian Nordic initiates phase II PROSTVAC combo prostate cancer trial

Centerwatch - Wed, 2017-04-19 14:09

Bavarian Nordic initiated a phase II clinical trial of its prostate cancer immunotherapy candidate, PROSTVAC (rilimogene), in combination treatment with YERVOY (ipilimumab) and/or OPDIVO (nivolumab), both of which are immune checkpoint inhibitors from Bristol-Myers Squibb, as neoadjuvant therapy in patients with localized prostate cancer. A lead-in stage will evaluate the safety of the combination of […]

The post Bavarian Nordic initiates phase II PROSTVAC combo prostate cancer trial appeared first on CenterWatch News Online.

Categories: Industry News

Certara introduces pharmacokinetic (PK) data solution

Centerwatch - Wed, 2017-04-19 08:55

Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, announced the launch of a new solution for preparing, analyzing and submitting PK data in Clinical Data Exchange Standards Consortium (CDISC) format. CDISC supports the acquisition, exchange, submission and archiving of nonclinical and clinical data. David Munro, […]

The post Certara introduces pharmacokinetic (PK) data solution appeared first on CenterWatch News Online.

Categories: Industry News

Nivalis Therapeutics, Alpine Immune Sciences to merge

Centerwatch - Wed, 2017-04-19 08:25

Nivalis Therapeutics and Alpine Immune Sciences, a privately-held biotechnology company developing novel therapies using its next-generation immune system modulation platform, have entered into a definitive merger agreement under which Alpine will merge with a wholly-owned subsidiary of Nivalis in an all-stock transaction. The merger will result in a combined company with a novel protein-based discovery […]

The post Nivalis Therapeutics, Alpine Immune Sciences to merge appeared first on CenterWatch News Online.

Categories: Industry News

ePatientFinder, Rep Network partner to expand clinical trial access

Centerwatch - Tue, 2017-04-18 14:05

ePatientFinder, an EHR-driven clinical trial site optimization and patient identification company, and Rep Network, the independent sales and knowledge source for the healthcare industry, announced an alliance that will expand clinical trial access to millions of additional patients across the country. The partnership provides the Rep Network’s team of more than 2,000 independent sales reps […]

The post ePatientFinder, Rep Network partner to expand clinical trial access appeared first on CenterWatch News Online.

Categories: Industry News

CRISPR Therapeutics, Casebia Therapeutics partner with StrideBio

Centerwatch - Tue, 2017-04-18 14:02

CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer for developing CRISPR-based therapeutics in select disease areas, have signed a collaboration agreement with StrideBio, a U.S.-based company developing novel AAV vectors for in vivo gene delivery applications. Under the terms of […]

The post CRISPR Therapeutics, Casebia Therapeutics partner with StrideBio appeared first on CenterWatch News Online.

Categories: Industry News

HitGen, Pfizer collaborate to build and screen novel DNA-encoded libraries

Centerwatch - Tue, 2017-04-18 13:54

HitGen has entered into a multi-year research collaboration and license agreement with Pfizer to build and screen novel DNA-encoded libraries (DELs) in order to potentially discover unique small molecule leads to be used in drug development. Through the collaboration, HitGen and Pfizer scientists will apply HitGen’s advanced technology platform and research capabilities in the design, […]

The post HitGen, Pfizer collaborate to build and screen novel DNA-encoded libraries appeared first on CenterWatch News Online.

Categories: Industry News

Medidata to acquire Mytrus

Centerwatch - Tue, 2017-04-18 13:51

Medidata, a global provider of cloud-based solutions and data analytics for clinical research, has agreed to acquire Mytrus, an eClinical technology company specializing in patient-centered electronic informed consent (eConsent) and virtual trials. Medidata will integrate Enroll, Mytrus’ eConsent solution, into the Medidata Clinical Cloud as part of its ongoing commitment to modernize clinical trials for patients, sites and […]

The post Medidata to acquire Mytrus appeared first on CenterWatch News Online.

Categories: Industry News

Synergy Pharmaceuticals appoints Gary G. Gemignani chief financial officer

Centerwatch - Tue, 2017-04-18 13:39

Synergy Pharmaceuticals announced that Gary G. Gemignani has been appointed as executive vice president and chief financial officer, effective April 17, 2017. Gemignani replaces senior vice president, Finance, Bernard Denoyer, who will assist in the transition process until his retirement on July 1, 2017. Gemignani’s career in healthcare spans over three decades, including senior management […]

The post Synergy Pharmaceuticals appoints Gary G. Gemignani chief financial officer appeared first on CenterWatch News Online.

Categories: Industry News

Bristol-Myers Squibb, Nordic Bioscience collaborate on fibrosis biomarker technology

Centerwatch - Tue, 2017-04-18 13:36

Bristol-Myers Squibb and Nordic Bioscience, a Danish company specializing in biomarker technologies, announced a collaboration agreement to develop biomarker technology to potentially aid in the diagnosis and monitoring of fibrotic diseases including non-alcoholic steatohepatitis (NASH). Nordic Bioscience has over 25 years’ experience in biomarker development and clinical trials with extensive expertise in rheumatology and fibrosis. A […]

The post Bristol-Myers Squibb, Nordic Bioscience collaborate on fibrosis biomarker technology appeared first on CenterWatch News Online.

Categories: Industry News

FDA issues complete response letter for Baricitinib

Centerwatch - Tue, 2017-04-18 13:32

Eli Lilly and Incyte announced that the FDA has issued a complete response letter for the New Drug Application (NDA) of the investigational medicine baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis (RA). The letter indicates that the FDA is unable to approve the application in its current form. Specifically, the […]

The post FDA issues complete response letter for Baricitinib appeared first on CenterWatch News Online.

Categories: Industry News

Axovant Sciences appoints Dr. David Hung CEO, Marion McCourt as president and COO

Centerwatch - Tue, 2017-04-18 13:17

Axovant Sciences, a clinical stage biopharmaceutical company focused on the treatment of dementia, announced that David Hung, M.D., has been named chief executive officer of Axovant Sciences, effective April 7, 2017. Dr. Hung, who also joined Axovant’s board of directors, succeeds founding chief executive officer Vivek Ramaswamy. Ramaswamy will continue to serve on Axovant’s board of […]

The post Axovant Sciences appoints Dr. David Hung CEO, Marion McCourt as president and COO appeared first on CenterWatch News Online.

Categories: Industry News
Syndicate content